What is Monogram mBos?

Monogram mBos: autonomy-boundary case within the surgical cluster

Monogram mBos is the Monogram Bone Orthopedic Surgical platform, an autonomy-boundary case within the surgical cluster from Monogram Orthopaedics. Per DEPLOY's surgical cluster framework, mBos extends the cluster's architectural axes from FDA-clearance-posture + clinical-domain + commercial-model + orthopedic sub-cohort triangle to include the autonomy-boundary axis as a fourth-tier framework distinction.

---

Doug Unis CMO/founder (NOT CEO; pre-acquisition CEO Benjamin Sexson)

Per Agent A precision corrections, Monogram leadership entity-identification requires precise scoping. Doug Unis is CMO/founder of Monogram. Pre-acquisition CEO was Benjamin Sexson, NOT Doug Unis. Per cap-flag-as-trust-signal, trade-press coverage that frames Doug Unis as "CEO" operates outside Agent A primary-source-anchored verification of the founder + CMO + pre-acquisition-CEO role distinctions. The CMO-founder vs CEO distinction matters editorially at the entity verification layer. The framework-in-action correction is documented at canonical worked-example depth in Monogram's Doug Unis is CMO/founder, not CEO.

---

Zimmer Biomet acquired Monogram October 7, 2025 (~$168M EV + CVR)

Per Agent A precision corrections, Zimmer Biomet acquired Monogram with closing on October 7, 2025. The acquisition structure: ~$168M enterprise value plus contingent value rights (CVR). Per DEPLOY's acquisition history Project B methodology pillar, ZB × Monogram operates as the CANONICAL worked example for the contingent valuation_basis state (full_acquisition structure + contingent valuation_basis composition; CVR earnout component tracked at sub-acquisition granularity subject to ongoing milestone-achievement verification). Per DEPLOY's framework, the acquisition timing matters editorially at the cohort consolidation layer:

• The October 2025 closing places Monogram inside Zimmer Biomet's portfolio post-acquisition.
• The CVR structure means upside payments contingent on future regulatory or commercial milestones; specific CVR terms operate at lower verification posture pending primary-source confirmation.
• Per the Zimmer Biomet ROSA framework: Zimmer Biomet autonomy enters via the SEPARATE Monogram acquisition, NOT via ROSA. The Monogram + ROSA distinction is preserved in the entity record so the AI-augmented-not-autonomous framing holds across the orthopedic sub-cohort triangle (Mako + CORI + ROSA) consistently while Monogram operates the autonomy-boundary case distinctly.

---

FDA-cleared March 17, 2025 semi-autonomous version: ROBOT cuts, NOT surgeon

Per Agent A precision corrections, Monogram mBos semi-autonomous version was FDA-cleared on March 17, 2025. The semi-autonomous clearance scope:

• KUKA-based robotic arm: the platform uses a KUKA industrial robotic arm as the bone-cutting executor.
• Bone cut execution: the robotic arm executes the bone cut under AI control within a surgeon-approved CT plan and surgeon supervision.
• The robot cuts, NOT the surgeon: this is structurally distinct from AI-augmented surgeon-controlled orthopedic systems.

Per DEPLOY's framework, the autonomy-boundary distinction matters editorially at the cohort architectural-axis layer: the robot-cuts vs surgeon-cuts distinction is the foundational architectural distinction within the surgical cluster, structurally distinct from:

• AI-augmented surgeon-controlled (orthopedic sub-cohort triangle): Stryker Mako + Smith+Nephew CORI + Zimmer Biomet ROSA; software plans + tracks + bounds; surgeon makes the cuts.
• Replacement-robotics teleoperated (soft-tissue replacement-robotics): Intuitive da Vinci + Medtronic Hugo + J&J Ottava + CMR Versius; surgeon teleoperates robotic arms via console.
• Assistive laparoscopy co-pilot: Moon Surgical Maestro; surgeon directly manipulates laparoscopic instruments with co-pilot augmentation.
• Autonomous-execution (autonomy-boundary case): Monogram mBos; KUKA robotic arm executes the bone cut autonomously under AI control + surgeon-approved CT plan + surgeon supervision.

The four-way distinction surfaces the surgical cluster's autonomy-boundary architectural axis as load-bearing.

---

CRITICAL CAP-FLAG: 'semi-autonomous' is ZB/trade-sourced framing (NOT FDA-letter-verbatim)

Per Agent A precision corrections, the 'semi-autonomous' descriptor is Zimmer Biomet + trade-press-sourced framing, NOT FDA-letter-verbatim. Per cap-flag-as-trust-signal, the verification-posture distinction matters editorially:

• ZB/trade-sourced framing: 'semi-autonomous' is the commercial-positioning descriptor used in Zimmer Biomet investor materials + trade-press coverage of the Monogram + ZB transaction.
• Monogram's own PR framing: 'robotic-assisted TKA' (total knee arthroplasty) is Monogram's own product-positioning language.
• FDA letter verification posture: the specific FDA clearance letter wording operates at primary-source verification posture; specific FDA-letter language is the load-bearing primary-source anchor for autonomy-classification claims.

Per DEPLOY's framework, the trade-press-sourced vs FDA-letter-verbatim distinction operates as editorial signal at the autonomy-claim verification layer. Trade-press coverage that frames mBos as "semi-autonomous" without acknowledging the trade-source vs FDA-letter framing distinction operates outside DEPLOY's verification-posture discipline.

---

Fully-autonomous version NOT cleared (development ~2027/2028)

Per Agent A precision corrections, the fully-autonomous version of mBos is NOT cleared as of mid-2026. Development timeline operates at ~2027/2028 aspirational; per cap-flag-as-trust-signal, aspirational timeline framing operates at lower verification posture pending primary-source confirmation.

First live-patient case: July 2025 India CDSCO trial. Per Agent A precision corrections, the first live-patient case is the India CDSCO trial in July 2025, NOT US FDA. This is a single index case with no peer-reviewed outcomes. Per cap-flag-as-trust-signal, the trial verification distinction matters editorially:

• India CDSCO trial vs US FDA pathway: structurally distinct regulatory verification scope; India CDSCO operates a distinct regulatory verification framework from US FDA.
• Single index case: one patient case; no peer-reviewed outcome publication.
• Forward-aspirational fully-autonomous timeline: ~2027/2028 is aspirational; specific FDA-pathway-to-fully-autonomous-clearance timing operates at lower verification posture.

---

Pre-commercial maturity (no units sold)

Per Agent A precision corrections, Monogram mBos is pre-commercial; no units sold as of mid-2026. Per DEPLOY's framework, the pre-commercial framing matters editorially at the deployment-maturity layer:

• Maturity classification: research-tier within the verified-vs-claimed framework; pre-commercial is the load-bearing verified-deployment posture.
• Distinct from cohort entries at verified-pilot or verified-commercial-shipped maturity: Mako + CORI + ROSA all at verified-commercial-shipped maturity within the orthopedic sub-cohort triangle; Monogram mBos operates at the pre-commercial / research-tier maturity layer despite the FDA clearance state.

Per cap-flag-as-trust-signal, the pre-commercial framing is the load-bearing verified maturity posture; trade-press coverage citing specific unit-pricing or commercial-deployment timelines without Monogram or Zimmer Biomet primary-source confirmation operates outside verification posture.

---

Cohort positioning: autonomy-boundary case + 4th architectural axis

Per the surgical cluster framework, Monogram mBos anchors:

• Autonomy-boundary case within surgical cluster: extends the cluster's architectural axes from 3 to 4 axes (autonomy-boundary added as 4th-tier framework distinction).
• Robot-cuts-not-surgeon distinction: foundational autonomy-boundary architectural distinction; KUKA robotic arm executes bone cuts under AI control within surgeon-approved CT plan + supervision.
• Pre-commercial / research-tier maturity: deployment-verification posture distinct from verified-commercial orthopedic sub-cohort triangle entries.
• Zimmer Biomet portfolio acquisition (Oct 7 2025; ~$168M EV + CVR): post-acquisition entity-positioning within ZB; preserves separation from ROSA AI-augmented positioning.
• Four-way autonomy-boundary distinction: robot-cuts + AI-augmented surgeon-controlled + replacement-robotics teleoperated + assistive laparoscopy co-pilot as architectural distinction within the surgical cluster.

Contrast with cohort:

• Stryker Mako + Smith+Nephew CORI + Zimmer Biomet ROSA: orthopedic sub-cohort triangle; AI-augmented surgeon-controlled (surgeon makes the cuts); verified-commercial-shipped maturity.
• Intuitive da Vinci + Medtronic Hugo + J&J Ottava + CMR Versius: replacement-robotics teleoperated soft-tissue; surgeon teleoperates console.
• Moon Surgical Maestro: assistive laparoscopy co-pilot; surgeon directly manipulates instruments.
• Monogram mBos: autonomy-boundary; robot executes bone cuts under AI control.

Consumer pricing surface for Monogram mBos is forthcoming via Agent B's planned coverage when commercial-deployment maturity warrants; per cap-flag-as-trust-signal, the consumer-price-page operates at honest-absence pending Monogram pre-commercial maturity transition. Registry institutional depth at Monogram registry company + mBos registry model.

For the canonical surgical cluster context, see the surgical robotics cluster. For the AI-augmented orthopedic sub-cohort triangle contrast, see what is Stryker Mako + what is Smith+Nephew CORI + what is Zimmer Biomet ROSA. For the canonical category umbrella, see what is physical AI. For methodology canonical references applicable to Monogram mBos: the 4-way autonomy-boundary taxonomy (CANONICAL autonomous-execution worked example: robot cuts under AI control within surgeon-approved CT plan + supervision; the ROBOT cuts NOT the surgeon) + the 9-tier source-quality rubric (FDA + ZB SEC + Monogram pre-acquisition source classification).